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ABSTRACT
Endoscopic ultrasound-guided fine needle
aspiration is a multistep procedure that
involves proper clinical indication, correct
selection of needles, adapting evidence-based
techniques such as the fanning maneuver and
not routinely using suction or the stylet for
tissue sampling, and establishing reliable
cytopathology support. Integrating
cytopathology in the training curriculum and
developing a more flexible platform of needles
and echoendoscopes are likely to further
advance the field of endosonography. This
review aims to summarize the technical issues
that are key to performing high-quality
endoscopic ultrasound-guided fine needle
aspiration.
Keywords: Cytology; Endoscopy training;
Endoscopic ultrasound; Fine needle aspiration;
Fine needle biopsy
INTRODUCTION
Endoscopic ultrasound (EUS)-guided fine needle
aspiration (FNA) is an indispensible tool for
tissue acquisition from within and adjacent to
the gastrointestinal tract. EUS-FNA may be
considered a disruptive innovation [1] in the
practice of pancreatic pathology, such that the
National Comprehensive Cancer Network has
incorporated EUS-FNA cytology in its diagnostic
algorithm for pancreatic cancer [2].
Undoubtedly, the role of EUS-FNA will expand
as the accuracy of EUS tissue acquisition
increases. For example, the combination of
EUS with endobronchial ultrasound-FNA will
likely replace surgical mediastinal staging in
patients with nonsmall cell lung cancer in the
future [3, 4]. Recent studies have also shown the
utility of EUS-guided liver biopsy in patients
with abnormal liver function tests undergoing
EUS [5, 6].
Obtaining a high-quality, diagnostic
specimen is the foundation of performing
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EUS-FNA. In-room confirmation of diagnostic
adequacy is a defining feature that establishes
EUS-FNA as a fundamental part of integrated,
multidisciplinary patient care. The benefits
include procedural efficiency whereby
diagnostic adequacy, rather than a
predetermined number, governs how many
FNA passes are performed. Procedural time and
complications are reduced if a diagnosis is
rapidly confirmed. If initial samples are
nondiagnostic, the sampling location or
needle type can be changed in a timely
manner, and avoid repeated noncontributory
passes. On-site diagnosis limits the need for
repeated EUS, with its associated morbidity and
cost. Furthermore, the preliminary diagnosis
enables collection of additional samples for
ancillary testing, such as flow cytometry in a
patient with monotonous lymphocytes on in-
room cytology assessment. Providing an
immediate preliminary diagnosis to patients
and their families contributes to quality
patient care, and allows timely referral for
additional imaging and consultation with
surgery or oncology.
There are several factors that may determine
the outcomes of EUS-FNA, such as needle
selection, maneuvers to procure quality tissue,
and the presence of an on-site cytopathologist.
This review aims to summarize the technical
issues that are key to performing high-quality
EUS-FNA. This review is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
TECHNICAL DIFFICULTY
AT DIFFERENT LOCATIONS
The degree of technical difficulty of EUS-FNA
varies according to the location of the
targeted lesion. Generally, transesophageal
and transgastric FNAs are technically easier
than transduodenal FNA. The position of the
scope is relatively straight when accessing the
majority of lesions via the esophagus or
stomach. An exception is access from the
gastric fundus, where near complete
retroflexion may be required. Acute
angulation of the tip of the scope, significant
torsion through the scope shaft, and maximal
elevator use increases the technical difficulty.
This is predominantly an issue in the
duodenum. The main challenges are passing
the needle assemblage through the scope to
attach to the working channel, and smoothly
advancing the needle into the targeted lesion,
while maintaining scope position and needle
control and maneuverability. Releasing the
up-down control to straighten the tip of the
scope, with or without withdrawing the scope
into a neutral position enables the needle to
be passed and attached to the working
channel, and the scope is then repositioned
for the FNA. If the needle doesn’t advance
into the lesion, straightening the scope from a
long to a short position often reduces the
scope tip angulation and the resistance to
passage of the needle. A 25G needle is suitable
for sampling the majority of lesions accessed
from the second part of the duodenum, and a
flexible 19G needle may be beneficial if
histology is required [7].
NEEDLE SELECTION
EUS-FNA can be performed using a 25G, 22G, or
a 19G needle. The decision to use a specific
needle is guided by a number of considerations.
The needle should provide an adequate tissue
sample to establish a definitive diagnosis, have
the degree of flexibility required for lesion
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access, a low risk of complications, and the
ability to obtain core tissue when necessary.
Seven randomized trials and two meta-
analyses [8–16] have evaluated different
needles for EUS-FNA (Table 1). Five
randomized trials comparing 22G and 25G
needles [8–10, 13, 14] found the needles had a
similar overall diagnostic accuracy and a trend
in favor of the 25G needle for transduodenal
sampling. Two meta-analyses have compared
the 25G and 22G needles for EUS-FNA of solid
pancreatic masses, and found a higher
diagnostic sensitivity [15] and accuracy [16]
with the 25G needle.
A randomized trial compared the 19G and 22G
needles in 117 patients with pancreatic and
peripancreatic masses [11]. Superior diagnostic
accuracy and tissue acquisition was obtained with
the 19G needle; however, there was a high rate of
technical failure for lesions in the head of
pancreas. The role of the standard 19G FNA
needle for yielding histological samples was
prospectively assessed in a single-arm study by
Larghi et al. [17]. Of the 120 patients who
underwent EUS-FNA, the procedure was
technically successful in 119 patients (99.2%)
and adequate histological sample was obtained in
116 (97.5%) of these patients. A major limitation
of the study was that patients with pancreatic
head or uncinate masses were excluded. A recent
multicenter randomized trial compared a flexible
19G needle made of nitinol (Flex 19; Boston
Scientific, Natick, MA, USA) to a 25G needle for
FNA of solid pancreatic masses [12]. While
diagnostic accuracy and technical failure was
similar between needles, the 19G needle yielded
histological core tissue in significantly more
patients (86.1% vs. 33.3%, P\0.001).
The 19G Trucut biopsy needle (Cook
Medical, Winston-Salem, NC, USA) was
developed to attain core histologic tissue [18];
however, the needle’s rigidity limited its use for
transduodenal sampling [19]. A new 19G fine
needle biopsy (FNB) device (ProCore; Cook
Medical, Winston-Salem, NC, USA) with
reverse bevel technology was subsequently
developed. Histological samples were
successfully obtained in a majority of patients
with a diagnostic accuracy of [90% [20],
however, some technical difficulties were
encountered with transduodenal passes. 22G
and 25G ProCore needles are also available,
which facilitate transduodenal sampling. Three
recent randomized trials comparing the 22G or
25G ProCore needles to standard FNA needles in
pancreatic masses and peripancreatic
lymphadenopathy [21–23] have concluded that
there is no significant difference in establishing
a correct diagnosis between needles. In a study
using the 25G ProCore needle, while a
cytological diagnosis was established in 96% of
50 patients, histological core tissue was procured
in only 32% of patients [22]. A study in 144
patients using the 22G ProCore needle vs. a
standard 22G FNA needle showed similar
diagnostic accuracy between needles, and
fewer passes were required to obtain sufficient
tissue with the ProCore needle (1.2 ± 0.5 passes




The center of a malignant mass is usually more
degenerated than the periphery and hence
more likely to provide nondiagnostic tissue
when sampled [24]. Furthermore, repeated
sampling along the same trajectory through a
lesion is more likely to result in bloodier
specimens. Two studies have explored whether
aspirating a lesion at the peripheries or across
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multiple trajectories improves the diagnostic
yield [25, 26]. In a randomized trial of 54
patients with solid pancreatic masses, the
fanning technique resulted in a significantly
higher first pass diagnosis compared with the
standard FNA technique (85.7% vs. 57.7%,
P = 0.02) [26]. The fanning technique of FNA
involves positioning the needle at four different
areas within a mass and then moving the needle
back and forth four times in each area to
procure tissue. We term this the ‘4 9 4’ rule.
Aspiration is usually initiated at a margin of the
tumor mass and then ‘fanned’ until the
opposite margin of the tumor is sampled. The
trajectory of the needle can be altered using
either the ‘up/down’ endoscope dial or the
elevator.
Suction
Applying suction during FNA increases the
quantity of the FNA sample; however, the
specimen is bloodier thereby diminishing the
aspirate quality. A randomized trial on FNA of
lymph nodes demonstrated that suction
resulted in a bloodier specimen and no
difference in diagnostic accuracy [27]. In a
randomized trial by Lee et al. [28], 81 patients
with pancreatic masses underwent EUS-FNA
with and without suction in all lesions.
Suction resulted in higher diagnostic samples
and cellularity, however, specimen bloodiness
was increased. In another randomized trial on
pancreatic masses, there was no difference in
diagnostic yield, cellularity, or specimen
bloodiness, irrespective of whether or not
suction was used [29].
Although manufacturer guidelines must be
followed when using specially designed biopsy
needles, there is no objective data on the best
technique to use a 19G needle. In our
experience, suction or a stylet should generally
be avoided to minimize bloodiness [30]. The
needle should be carefully ‘fanned’ within the
mass, moving back and forth only two to three
times (4 9 2 rule), and avoid repeated ‘jabbing’
at one area. It is usually unnecessary to perform
more than three FNB passes in a lesion, as
repeated sampling increases the sample
bloodiness. In routine clinical practice, suction
is used primarily for aspiration of cystic lesions.
Wet Suction and Slow Pull Techniques
Two modified FNA techniques have been
recently trialed. In the ‘wet suction’ technique
[31], the FNA needle is flushed with sterile
saline prior to puncturing the target lesion, and
suction is then applied. The authors
randomized 117 lesions to commence with
either the wet suction technique or ‘dry’ FNA
with suction, and subsequent passes using
alternating techniques. The wet suction
technique had significantly higher cellularity
and diagnostic yield, with no difference in
hemorrhage.
The ‘slow pull’ technique is performed by
gradually withdrawal of the stylet as the needle
is repeatedly passed through the target lesion.
The rationale is the withdrawing stylet produces
a low level of negative pressure within the
needle which increases tissue acquisition and
limits specimen bloodiness. In a retrospective
study of 97 EUS-FNAs performed with either the
slow pull technique or suction using a 25G FNA
needle [32], the slow pull technique resulted in
lower cellularity and bloodiness but higher
diagnostic sensitivity.
Stylet
The role of the stylet in the FNA needle
assemblage is to prevent the hollow tip of the
needle from filling with esophageal, gastric, or
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duodenal wall tissue before it enters the target
lesion. However, three randomized studies have
shown the use of a stylet does not improve the
diagnostic yield for malignancy, and increases
the bloodiness of the tissue specimen [33–35]. A
fourth study [28] found the diagnostic yield was
higher using the stylet, and specimen
bloodiness was decreased if the needle was
flushed with air rather than using the stylet to
express the specimen. Reinserting the stylet for
each FNA pass is time consuming and may
increase the risk of needle-stick injury. The
weight of evidence suggests limited advantage
to reinserting the stylet between passes, and it
should be kept for controlled expression of
aspirates onto the slides.
Number of Passes
The aim of performing FNA is to obtain a
diagnostic specimen using the fewest number of
passes possible. An on-site cytopathology team,
to assess specimen adequacy, establish an on-
site diagnosis, and advise on whether additional
sampling is needed, improves the yield and
decreases the number of passes required [36]. In
the absence of an on-site cytopathologist,
adequate passes should be performed to avoid
the need for repeat procedures. Studies have
shown that with solid pancreatic mass lesions, 7
passes provided a sensitivity and specificity of
83% and 100%, respectively, and 5 passes on
lymph nodes yielded sensitivity and specificity
of 77% and 100%, respectively [37]. Another
study [38] recommended 5–6 passes for
pancreatic mass lesions and 2–3 passes for
lymph nodes. In a study of 209 consecutive
EUS-FNA at multiple locations, 90% of adequate
samples were obtained within 6 passes, after
which there was only a marginal increment in
obtaining adequate samples [39]. When on-site
cytopathology support is not available, a
general recommendation would be to perform
at least four to five FNA passes for cell block or
three FNB passes for histopathological analysis.
SAFETY
The safety profile of EUS-FNA is excellent [40,
41]. The majority of complications are
encountered during aspiration of cystic
lesions, and prophylactic antibiotics are
recommended to reduce the risk of sepsis [40].
Clinically significant intracystic hemorrhage is
rare and bleeding usually resolves
spontaneously. Low-dose aspirin can be safely
continued, but clopidogrel must be stopped
7 days prior to EUS-FNA. Low-molecular weight
heparin and unfractionated heparin must be
discontinued 12–24 and 6 h prior to FNA,
respectively. Warfarin should be withheld
5 days before in low-risk patients, and bridged
with heparin in patients at high risk for
thrombotic events [42]. A systematic review
concluded that there is a low risk of pancreatitis
following pancreatic EUS-FNA, at 0.44% [43]. A
recent meta-analysis comparing rates of
complications between standard 19G and 22G/
25G needles for pancreatic EUS-FNA [44]
showed no significant difference in rates of
pancreatitis, bleeding, infection, perforation, or
abdominal pain. Experience with the 19G
needle for FNA is limited, and its safety profile
will become more defined with increased use.
ENDOSONOGRAPHER EXPERIENCE
There is a learning curve for performing EUS-
FNA. While recommendations of the number of
supervised EUS-FNAs vary [24, 45–47],
competence in linear EUS is essential before
commencing FNA. Two learning curve studies
have been performed, both in pancreatic
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masses. In a study of 57 patients who
underwent EUS-FNA by a self-taught
endosonographer, the diagnostic sensitivities
for malignancy from the first to the last 10
quintiles were 30%, 40%, 70%, 90%, and 80%,
respectively [48]. In second study of 300
consecutive patients who underwent EUS-FNA
by a trained endosonographer, the median
number of passes required to establish a
diagnosis decreased significantly with operator
experience but without any difference in
diagnostic accuracy [49]. This suggests that
while the diagnostic accuracy may plateau
over time, the procedural expertise continues
to improve with experience.
CYTOPATHOLOGY
The success of EUS-FNA is largely dependent
upon the experience and technique of the
endosonographer, as well as the proficiency
and diagnostic experience of the pathologist
(Fig. 1) [50]. The presence of on-site
cytopathology increases the diagnostic
accuracy of the procedure while decreasing the
number of inadequate and suboptimal
specimens [51]. The nondiagnostic rate has
been reported as low as 1% for FNAs with
rapid on-site evaluation (ROSE) as compared
with 20% without ROSE [52]. This is particularly
important, as specimens obtained by EUS-FNA
are often the only histologic proof of
malignancy, permitting tissue-based
(immunohistochemical, molecular, and
genomic) testing for optimal patient
management. A recent meta-analysis showed
that ROSE was associated with a 10% higher
tissue adequacy rates on average, but had no
impact on diagnostic accuracy [53].
ROSE is not available at many centers
secondary to the considerable time
commitment, cost, and inadequate
Fig. 1 EUS-FNA cytology preparation and assessment.
a Core-like material from a 19G needle expressed onto a
slide shows a tan-pink (arrow) section of tissue distinctly
different from the hemorrhagic tissue. b A portion of the
tan-pink tissue is smeared and the granular tissue fragments
are easily discernible. c ROSE shows a pleomorphic mucin-
producing carcinoma. d Multiple nonhemorrhagic tan-pink
cores were collected in CytoLyt (Cytyc Corporation;
Boxborough, MA, USA) for cell block. e The cell block
showed normal liver (left) and adjacent cholangiocarcinoma
(right). Samples such as this are excellent for molecular and
genomic studies
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reimbursement or compensation by insurance
or medicare. This has led to practices relying
upon either endoscopy nurses, technologists,
and/or endosonographers to independently
handle, collect, and evaluate aspirated
material. Many practices have attempted to
avoid the need of on-site evaluation by
performing FNB and/or core needle biopsy.
However, regardless of the modality used, the
sample obtained will be limited in size and
cellular yield. Therefore, the independent
endosonographer may benefit from knowing
the basic cytopathologic techniques for
handling and processing tissue to optimize the
specimens sent for off-site evaluation [54].
The most important factor in handling,
processing, and evaluating the procured tissue
is consistency. Having one dedicated person
handling the aspirated material establishes a
protocol for preparation and minimizes the
artifacts of improper tissue handling and
collection. In addition, the level of
independence must be defined. Cytopathology
assistance can be on-site, at a close proximal
location, or remote (telepathology) assistance.
Therefore, the independent endosonographer
should be aware of the operational structure of
their EUS center and thereby the supplies and
equipment required for correct specimen
handling.
While most endosonographers do not
routinely practice in-room basic
cytomorphology analysis, a study has shown
that microscopic evaluation of smears by
independent practitioners (with basic
cytomorphology training) without access to
on-site assistance significantly improves
diagnostic accuracy [55]. Short intensive EUS-
cytopathology courses for endosonographers
have also been shown to provide effective
training in specimen handling and evaluation
for diagnostic adequacy [56]. Integrating
focused EUS-cytopathology didactics into
advanced endoscopy fellowships has been
suggested, knowing that many newly trained
graduates join practices without cytopathology
support. This is becoming increasingly common
as changes in medical reimbursement, such as
bundled payments, changes in capitations, and
global budgets, are taking place.
Many cytotechnologists and pathologists
utilize gross visible assessment as a valuable
mechanism to determine if cellular material has
been obtained and to reduce procedural time.
The slide that macroscopically appears to be
cellular is evaluated first under the microscope.
This may allow a diagnosis to be reached more
quickly, minimize the number of unnecessary
passes, and allow for diagnostic material to be
diverted to cell block. In addition to gross
assessment of smears, experienced personnel
who routinely handle the aspirated material
become adept in evaluating core biopsy
specimens and aspirated material collected in
solution for ancillary testing, and may come to
recognize bloody, dilute, sclerotic, and mucoid
samples based upon the consistency and
manner that the material extrudes from the
needle. As an example, both sclerotic and
necrotic material may appear tan-white in
color, but sclerotic stromal tissue is firm, not
easily smeared, and as a core may sink to the
bottom of the collection tube. Likewise, the
experienced eye often can discriminate between
red hemorrhagic ‘‘core’’ tissue, and tan-pink
material that has a higher diagnostic yield.
Gross visual assessment is not equivalent to
microscopic evaluation, but with experience
personnel can readily predict an inadequate
specimen [57]. This can be invaluable,
particularly when determining if sufficient
material has been collected for cell block.
Cell block is often the best material for
ancillary testing. With concurrent advances in
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minimally invasive procedures and molecular
diagnostics, cell blocks are often required for
multiple tissue sections for
immunohistochemical and special staining,
molecular testing, and research. Cell blocks
typically maintain architectural integrity, so
can be compared to other tissue specimens in
a given patient. There is no standard method for
cell block preparation, and multiple methods
may exist even within a single institution. The
quality and cellular yield of the more
commonly used methods of cell block
preparation, such as plasma-thrombin,
histogel, or CellientTM (Hologic, Inc.; Bedford,
MA, USA) technology can be unsatisfactory
[58]. Until the cell block preparation method
is optimized, the responsibility of collecting
enough material for a diagnostic cell block
remains with the endoscopist.
THE FUTURE
Minimally invasive tissue acquisition is a
powerful tool, and the role of EUS-FNA will
continue to expand and evolve with technical
advances in needle and scope design, and
integration of cytopathology training and
diagnostics. Tissue acquisition relies upon
lesion access, which is particularly challenging
from the duodenum when an unstable or
acutely angulated scope position may be
required. This can be improved by addressing
the two key limiting factors: needle and scope
design. Needles require flexibility to smoothly
pass through the scope and into the lesion, and
respond to manipulation with the scope tip and
elevator to sample in different trajectories
through the lesion. Further advances in scope
design may include developing a thinner, more
flexible scope with increased range of
movement at the tip of the scope. Such
changes may also improve the safety of
passing the scope through the pharynx and
from the first to second part of the duodenum.
Integration of a mechanism to provide variable
stiffness through the shaft of the scope,
analogous to colonoscopes, may also increase
the scope stability and functionality.
Development of a scope capable of performing
both EUS and endoscopic retrograde
cholangiopancreatography, to allow combined
procedures without exchanging scopes, would
be a game changer. Essential to EUS
performance is the quality of ultrasound
imaging, and further advances include
expanding the angle of EUS imaging and
increasing image resolution. Finally, the march
toward in-room pathology diagnosis continues,
and providing high-quality EUS-FNA specimens
is the first step. Integration of basic
cytopathology training and utilization is the
next step, and in the future this may be
followed by an increased shift of pathological
evaluation from the laboratory into the
endoscopy room to allow real-time diagnosis.
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